截至2021年嵌合抗原受体T细胞（CAR T细胞）临床试验活动概述。
An overview of CAR T-cell clinical trial activity to 2021.
作者信息
Adami Antonella, Maher John
机构信息
King's College London, School of Cancer and Pharmaceutical Sciences, CAR Mechanics Lab, Guy's Cancer Centre, London, UK.
Department of Clinical Immunology and Allergy, King's College Hospital NHS Foundation Trust, London, UK.
出版信息
Immunother Adv. 2021 Mar 9;1(1):ltab004. doi: 10.1093/immadv/ltab004. eCollection 2021 Jan.
Abstract
Immunotherapy of cancer using chimeric antigen receptor-engineered T-cells has transformed the management of selected haematological malignancies, triggering intense clinical trial activity in this arena. This article summarises trial activity that has been published to date across the spectrum of haematological and solid tumour types.
摘要
使用嵌合抗原受体工程改造的T细胞进行癌症免疫治疗已经改变了特定血液系统恶性肿瘤的治疗方式，引发了该领域的密集临床试验活动。本文总结了迄今为止已发表的涵盖血液系统和实体瘤类型的试验活动。
相似文献
1
An overview of CAR T-cell clinical trial activity to 2021.
Immunother Adv. 2021 Mar 9;1(1):ltab004. doi: 10.1093/immadv/ltab004. eCollection 2021 Jan.
2
Cell Therapy for Colorectal Cancer: The Promise of Chimeric Antigen Receptor (CAR)-T Cells.
Int J Mol Sci. 2021 Oct 29;22(21):11781. doi: 10.3390/ijms222111781.
3
Versatile CAR T-cells for cancer immunotherapy.
Contemp Oncol (Pozn). 2018 Mar;22(1A):73-80. doi: 10.5114/wo.2018.73892. Epub 2018 Mar 5.
4
Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in patients with haematological and solid malignancies: protocol for a systematic review and meta-analysis.
BMJ Open. 2017 Dec 29;7(12):e019321. doi: 10.1136/bmjopen-2017-019321.
5
CAR-Expressing Natural Killer Cells for Cancer Retargeting.
Transfus Med Hemother. 2019 Feb;46(1):4-13. doi: 10.1159/000495771. Epub 2019 Feb 5.
6
CAR Based Immunotherapy of Solid Tumours-A Clinically Based Review of Target Antigens.
Biology (Basel). 2023 Feb 10;12(2):287. doi: 10.3390/biology12020287.
7
Enhancement of anti-sarcoma immunity by NK cells engineered with mRNA for expression of a EphA2-targeted CAR.
Clin Transl Med. 2025 Jan;15(1):e70140. doi: 10.1002/ctm2.70140.
8
Chimeric antigen receptor engineered T cells and their application in the immunotherapy of solid tumours.
Expert Rev Mol Med. 2022 Jan 28;24:e7. doi: 10.1017/erm.2021.32.
9
Current progress of chimeric antigen receptor (CAR) T versus CAR NK cell for immunotherapy of solid tumors.
Life Sci. 2024 Jan 15;337:122381. doi: 10.1016/j.lfs.2023.122381. Epub 2023 Dec 23.
10
Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Eur J Cancer. 2022 Jan;160:112-133. doi: 10.1016/j.ejca.2021.10.016. Epub 2021 Nov 25.
引用本文的文献
1
Solid tumor immunotherapy using NKG2D-based adaptor CAR T cells.
Cell Rep Med. 2024 Nov 19;5(11):101827. doi: 10.1016/j.xcrm.2024.101827.
2
Potential Therapeutic Targets for the Treatment of HPV-Associated Malignancies.
Cancers (Basel). 2024 Oct 14;16(20):3474. doi: 10.3390/cancers16203474.
3
Incorporating IL7 receptor alpha signaling in the endodomain of B7H3-targeting chimeric antigen receptor T cells mediates antitumor activity in glioblastoma.
Cancer Immunol Immunother. 2024 Apr 15;73(6):98. doi: 10.1007/s00262-024-03685-7.
4
CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn.
Nat Rev Clin Oncol. 2024 Jan;21(1):47-66. doi: 10.1038/s41571-023-00832-4. Epub 2023 Oct 30.
5
Activation-inducible CAR expression enables precise control over engineered CAR T cell function.
Commun Biol. 2023 Jun 5;6(1):604. doi: 10.1038/s42003-023-04978-w.
6
A systems and computational biology perspective on advancing CAR therapy.
Semin Cancer Biol. 2023 Sep;94:34-49. doi: 10.1016/j.semcancer.2023.05.009. Epub 2023 May 30.
7
Education for the translation of Advanced Therapy Medicinal Products.
Front Med (Lausanne). 2023 Apr 4;10:1125892. doi: 10.3389/fmed.2023.1125892. eCollection 2023.
8
Immunotherapy advances: One year on.
Immunother Adv. 2022 Jan 11;2(1):ltac001. doi: 10.1093/immadv/ltac001. eCollection 2022.
9
CAR T-Cell Therapies in Italy: Patient Access Barriers and Recommendations for Health System Solutions.
Front Pharmacol. 2022 Jun 23;13:915342. doi: 10.3389/fphar.2022.915342. eCollection 2022.
10
Catching Them Early: Framework Parameters and Progress for Prenatal and Childhood Application of Advanced Therapies.
Pharmaceutics. 2022 Apr 5;14(4):793. doi: 10.3390/pharmaceutics14040793.
本文引用的文献
1
Lymphodepletion strategies to potentiate adoptive T-cell immunotherapy - what are we doing; where are we going?
Expert Opin Biol Ther. 2021 May;21(5):627-637. doi: 10.1080/14712598.2021.1857361. Epub 2020 Dec 28.
2
Clinical development of CAR T cell therapy in China: 2020 update.
Cell Mol Immunol. 2021 Apr;18(4):792-804. doi: 10.1038/s41423-020-00555-x. Epub 2020 Sep 30.
3
Cancer cell therapies: the clinical trial landscape.
Nat Rev Drug Discov. 2020 Sep;19(9):583-584. doi: 10.1038/d41573-020-00099-9.
4
The therapeutic landscape for cells engineered with chimeric antigen receptors.
Nat Biotechnol. 2020 Feb;38(2):233-244. doi: 10.1038/s41587-019-0329-2. Epub 2020 Jan 6.
5
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.
N Engl J Med. 2011 Aug 25;365(8):725-33. doi: 10.1056/NEJMoa1103849. Epub 2011 Aug 10.
6
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.
Blood. 2010 Nov 18;116(20):4099-102. doi: 10.1182/blood-2010-04-281931. Epub 2010 Jul 28.
7
Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product.
J Immunol. 1998 Sep 15;161(6):2791-7.
8
Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors.
Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):720-4. doi: 10.1073/pnas.90.2.720.
9
Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions.
Biochem Biophys Res Commun. 1987 Dec 31;149(3):960-8. doi: 10.1016/0006-291x(87)90502-x.
Zotero 插件